About Adaptive Biotechnologies
Adaptive Biotechnologies: Revolutionizing Medicine with Immune System
Adaptive Biotechnologies is a leading biotechnology company that is transforming the field of medicine by harnessing the power of the immune system. The company's innovative approach to diagnostics and therapeutics has the potential to revolutionize how we diagnose, treat, and prevent diseases.
Founded in 2009 by Chad Robins and Harlan Robins, Adaptive Biotechnologies has quickly become a leader in the field of immunology. The company's mission is to decode the immune system so that it can be used as a natural diagnostic and therapeutic tool. By understanding how our immune system works, Adaptive Biotechnologies aims to develop new ways to diagnose diseases earlier, monitor treatment response more accurately, and create personalized therapies for patients.
The company's proprietary technology platform combines high-throughput sequencing with advanced bioinformatics algorithms to analyze T-cell receptors (TCRs) and B-cell receptors (BCRs). These receptors are unique proteins found on the surface of immune cells that recognize specific antigens or foreign substances in our body. By analyzing these receptors at scale, Adaptive Biotechnologies can identify patterns or signatures that are associated with different diseases or conditions.
One of Adaptive Biotechnologies' flagship products is its clonoSEQ® Assay. This FDA-cleared test uses next-generation sequencing technology to detect minimal residual disease (MRD) in patients with certain blood cancers such as acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). MRD refers to small amounts of cancer cells that may remain after treatment but cannot be detected by traditional methods such as imaging or blood tests. Detecting MRD early can help doctors make more informed decisions about treatment options and improve patient outcomes.
Another area where Adaptive Biotechnologies is making significant progress is in infectious disease diagnostics. The company has partnered with Microsoft on a project called ImmuneCODE™ which aims to map all possible TCRs associated with infectious diseases such as COVID-19. By creating a comprehensive database of TCRs from infected individuals around the world, researchers can better understand how our immune system responds to different pathogens and develop new diagnostic tools or vaccines.
In addition to diagnostics, Adaptive Biotechnologies is also developing novel immunotherapies for cancer patients based on its proprietary technology platform. The company's lead product candidate ADP-A2M4 targets solid tumors expressing MAGE-A4 antigen which is found in several types of cancer including lung cancer and head & neck cancer. ADP-A2M4 uses engineered T-cells from healthy donors that have been modified using CRISPR gene editing technology so they can recognize MAGE-A4 antigen on tumor cells more effectively.
Overall, Adaptive Biotechnologies' innovative approach has tremendous potential for improving patient outcomes across many areas of medicine including oncology, infectious disease, autoimmune disorders among others. With its strong scientific expertise combined with strategic partnerships across academia & industry sectors globally; this Seattle-based biotech firm continues pushing boundaries towards unlocking full potential within human immunity - paving way towards future advancements within healthcare industry!